LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in three poster presentations at the 102nd American Association for Cancer Research (AACR) Annual Meeting held in Orlando, Florida, April 2-6, 2011.
